{"id":535255,"date":"2010-04-20T08:54:22","date_gmt":"2010-04-20T12:54:22","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=74623"},"modified":"2010-04-20T08:54:22","modified_gmt":"2010-04-20T12:54:22","slug":"seattle-genetics-nabs-9-5m","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/535255","title":{"rendered":"Seattle Genetics Nabs $9.5M"},"content":{"rendered":"\n
Biotech<\/a>, cancer<\/a>, deals<\/a><\/div>\n

\t\tLuke Timmerman wrote:<\/strong><\/p>\n

Seattle Genetics, the developer of targeted cancer drugs in Bothell, WA, said today<\/a> that Genentech, the U.S. unit of Roche, has agreed to pay $9.5 million to extend a licensing agreement between the two companies. Genentech has renewed its right to develop what are called “empowered antibodies” in which an antibody is made to zero in on a certain target on cells, and is linked to a more potent cell-killing agent. Genentech will pay the expenses of developing and marketing the drugs, while Seattle Genetics (NASDAQ: SGEN<\/a>) will receive fees, milestone payments, and royalties on sales if they become FDA-approved products.<\/p>\n

Comments<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n\"\"<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Biotech, cancer, deals Luke Timmerman wrote: Seattle Genetics, the developer of targeted cancer drugs in Bothell, WA, said today that Genentech, the U.S. unit of Roche, has agreed to pay $9.5 million to extend a licensing agreement between the two companies. Genentech has renewed its right to develop what are called “empowered antibodies” in which […]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-535255","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/535255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=535255"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/535255\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=535255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=535255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=535255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}